Literature DB >> 2231810

Use of recombinant human erythropoietin (r-HuEPO) in a Jehovah's Witness refusing transfusion of blood products: case report.

J A Koestner1, L D Nelson, J A Morris, K Safcsak.   

Abstract

Recombinant human erythropoietin (r-HuEPO) administration to a Jehovah's witness refusing blood transfusions increased her nadir packed cell volume from 13% to 37% and reticulocyte count from 2% to 17.7%. R-HuEPO may provide an alternative safe and effective therapy in life-threatening anemia when blood transfusions are unacceptable to the patient.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2231810     DOI： 10.1097/00005373-199011000-00016

Source DB:  PubMed          Journal:  J Trauma        ISSN： 0022-5282


  4 in total

1.  Considerations in the surgical treatment of congenital heart disease in children of Jehovah's Witnesses.

Authors:  D A Cooley; C M Burnett
Journal:  Tex Heart Inst J       Date:  1992

Review 2.  Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.

Authors:  R Whittington; L B Barradell; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

3.  [Jehova's Witnesses and severe injury with impending hemorrhaging : how complex is the treatment?].

Authors:  C Zeckey; N Vanin; G Neitzke; P Mommsen; S Bachmann; M Frink; M Wilhelmi; C Krettek; F Hildebrand
Journal:  Chirurg       Date:  2011-06       Impact factor: 0.955

4.  Erythropoietin mimics the acute phase response in critical illness.

Authors:  John Michael Elliot; Tanit Virankabutra; Stephen Jones; Surasak Tanudsintum; Graham Lipkin; Susan Todd; Julian Bion
Journal:  Crit Care       Date:  2003-04-24       Impact factor: 9.097
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.